reports
Inventiva announces completion of enrollment in the Phase 3 NATiV3 cli...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compan...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3...
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoirePrincipaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils supporteront les demandes règlementaires d’autorisation de mise sur le marché Daix (France), New York City (New York, États-Unis), le 1 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Sociét...
- Jacob Mekhael
Inventiva FIRST LOOK: FY24 results confirm NATiV3 enrolment completion...
Inventiva reported FY24 results with a cash position of € 96.6m (YE23: €36m), providing a runway until mid 3Q25. The update comes in line with our expectations, and the progress made in recruitment for the phase 3 (NATiV3) trial of lanifibranor in MASH means the company continues to expect completion of enrolment in 1H25. This would secure the timeline for the topline readout, expected in 2H26. With the additional funding from the second tranche of the financing announced in October 2024 expecte...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Inventiva reports its 2024 full year results and provides a business u...
Inventiva reports its 2024 full year results and provides a business update Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce...
Inventiva publie ses résultats financiers annuels 2024 et fait le poin...
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le cadre de la première tranche du Financement Structuré pouvant atteindre un montant total de 348 millions d'euros Dernier patient screené dans l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor dans la MASH début janvier 2025 Projet de réorganisation stratégique des activités présenté au comité social e...
Inventiva announces the schedule of publication and presentation of it...
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2024 full-year fin...
Inventiva annonce la date de publication et de présentation de ses rés...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024 Daix (France), New York City (New York, Etats-Unis), le 19 mars 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui que son équipe de direction présentera les résultats financiers...
Inventiva announces the publication in Biomedicine & Pharmacotherapy o...
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfunction and fibrosis, and by directly targeting the splanchnic vasculature through its anti-angiogenetic effectsThese findings suggest that lanifibranor may be a promisi...
Inventiva annonce la publication dans Biomedicine & Pharmacotherapy de...
Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor L'étude a démontré que lanifibranor améliorait l'hypertension portale (HTP) dans des modèles murins d'HTP fibrotique et d'HTP non fibrotique préhépatique Il a été observé que lanifibranor réduit la pression portale en améliorant le dysfonctionnement des cellules endothéliales sinusoïdales hépatiques (Liver Sinusoidal Endothelial Cell « LSEC »), en réduisant la fibrose et en agissant directement sur...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Jacob Mekhael
- Thomas Vranken
Inventiva FIRST LOOK: Hepalys starts Ph1 with lani for Japan/South Kor...
Inventiva makes progress in its exclusive licensing agreement with Hepalys that was announced in September 2023 to develop and commercialize lanifibranor for the treatment of MASH patients in Japan and South Korea. The first participant has now been dosed in a Ph1 study to assess the safety, tolerability and PK/PD profile of the drug. Upon completion of this study and following Inventiva's EU/US pivotal NATiV3 readout, Inventiva and Hepalys could advance into a pivotal study for the region. We s...
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clin...
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASHThe study represents the first significant step of Inventiva’s and Hepalys’s partnership toward the development of lanifibranor in Japan and South Korea Daix (France), New York City (New...
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme ...
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1 Lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant à l'étude de Phase 1Des résultats positifs pourraient supporter le lancement d'une étude de Phase 3 pivot chez des patients atteints de MASH au JaponCette étude représente la première étape significative du partenariat entre Inventiva et Hepalys Pharma en vue du développement de lanifibranor au Ja...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva Preliminary FY24 to focus resources, phase 3 enrolment by 1H...
Inventiva reported FY24 revenue and cash results and provided a business update that included the decision to terminate pre-clinical research activities, which will enable the company to focus its resources on its lead program, lanifibranor in MASH. The company continues to guide for completion of enrolment in the phase 3 (NATiV3) trial of lanfibranor in MASH in 1H25, which means topline data is expected in 2H26, positioning NATiV3 as the next phase 3 readout in the MASH landscape. Following the...
Inventiva reports preliminary 2024 fiscal year financial results¹ and ...
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025Pipeline prioritization plan presented to the workers council to focus exclusively on the develo...
Inventiva publie ses résultats financiers préliminaires pour l'exercic...
Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée de la première tranche d'un financement structuré d'un montant maximal de 348 millions d'euros, avec un produit brut total de 116 millions d'eurosDernier patient screené dans la Phase 3 de l’étude clinique NATiV3 évaluant lanifibranor dans la MASH début janvier 2025 et randomisation du dernier patient attendue au cours du premi...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Inventiva Publishes phase 2 results of lanifibranor in T2D and MASLD i...
Inventiva announced the publication of the previously reported results from the phase 2 investigator-initiated 24 week study evaluating lanifibranor (800mg) in 38 patients with type 2 diabetes (T2D) and metabolic dysfunction-associated liver disease (MASLD) in the Journal of Hepatology. The results highlight the candidate's potential in patients with MASH and T2D, and are in line with other studies that have demonstrated its ability to improve glycemic control. This patient population will be a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.